drugset / Trial / NCT02732327
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the effect, safety, and tolerability of ceftazidime-avibactam (CAZ-AVI) plus vancomycin or linezolid compared to standard of care plus vancomycin or linezolid as empiric therapy in febrile neutropenic adults with cancer
Timeline
- Start
- 2016-05-17
- Primary completion
- 2016-06-27
- Completion
- 2016-06-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cefepime | Small molecule | 2 g | Intravenous |
| Subject | Ceftazidime-avibactam | Other / unclassified | 0.5 g | Intravenous |
| Subject | Ceftazidime-avibactam | Other / unclassified | 2 g | Intravenous |
| Comparator | Meropenem | Small molecule | 1 g | Intravenous |
| Comparator | Piperacillin/tazobactam | Unknown | 4.5 g | Intravenous |
| Background | Linezolid | Other / unclassified | 600 mg | Intravenous |
| Background | Vancomycin | Other / unclassified | 15 mg/kg | Intravenous |